156 related articles for article (PubMed ID: 25200537)
1. Paraneoplastic pruritus presenting with Hodgkin's lymphoma: a case report.
Villafranca JJ; Siles MG; Casanova M; Goitia BT; Domínguez AR
J Med Case Rep; 2014 Sep; 8():300. PubMed ID: 25200537
[TBL] [Abstract][Full Text] [Related]
2. Aprepitant for the Treatment of Chronic Refractory Pruritus.
He A; Alhariri JM; Sweren RJ; Kwatra MM; Kwatra SG
Biomed Res Int; 2017; 2017():4790810. PubMed ID: 29057261
[TBL] [Abstract][Full Text] [Related]
3. Treatment of pruritus in early-stage hypopigmented mycosis fungoides with aprepitant.
Jiménez Gallo D; Albarrán Planelles C; Linares Barrios M; Fernández Anguita MJ; Márquez Enríquez J; Rodríguez Mateos ME
Dermatol Ther; 2014; 27(3):178-82. PubMed ID: 24517320
[TBL] [Abstract][Full Text] [Related]
4. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study.
Santini D; Vincenzi B; Guida FM; Imperatori M; Schiavon G; Venditti O; Frezza AM; Berti P; Tonini G
Lancet Oncol; 2012 Oct; 13(10):1020-4. PubMed ID: 22995650
[TBL] [Abstract][Full Text] [Related]
5. Aprepitant for refractory nivolumab-induced pruritus.
Ito J; Fujimoto D; Nakamura A; Nagano T; Uehara K; Imai Y; Tomii K
Lung Cancer; 2017 Jul; 109():58-61. PubMed ID: 28577951
[TBL] [Abstract][Full Text] [Related]
6. Thalidomide for the control of severe paraneoplastic pruritus associated with Hodgkin's disease.
Gonçalves F
Am J Hosp Palliat Care; 2010 Nov; 27(7):486-7. PubMed ID: 20231735
[TBL] [Abstract][Full Text] [Related]
7. Aprepitant for severe refractory pruritus in a patient with relapsed Hodgkin lymphoma.
Al Nassan A; Bazzeh F; Sultan I
Pediatr Blood Cancer; 2024 Mar; 71(3):e30826. PubMed ID: 38146019
[No Abstract] [Full Text] [Related]
8. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.
Younes A; Connors JM; Park SI; Fanale M; O'Meara MM; Hunder NN; Huebner D; Ansell SM
Lancet Oncol; 2013 Dec; 14(13):1348-56. PubMed ID: 24239220
[TBL] [Abstract][Full Text] [Related]
9. Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature.
Song JS; Tawa M; Chau NG; Kupper TS; LeBoeuf NR
BMC Cancer; 2017 Mar; 17(1):200. PubMed ID: 28302100
[TBL] [Abstract][Full Text] [Related]
10. [Two cases of severe pruritus revealing Hodgkin's disease in children].
Amy de la Bretèque M; Bilan P; Galesowski A; Chevallier B; Drouot D; Sigal ML; Mahé E
Ann Dermatol Venereol; 2014 Dec; 141(12):765-8. PubMed ID: 25433928
[TBL] [Abstract][Full Text] [Related]
11. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J
Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022
[TBL] [Abstract][Full Text] [Related]
12. Aprepitant for erlotinib-induced pruritus.
Levêque D
N Engl J Med; 2010 Oct; 363(17):1680-1; author reply 1681. PubMed ID: 20961258
[No Abstract] [Full Text] [Related]
13. Substance P Antagonist Aprepitant Shows no Additive Effect Compared with Standardized Topical Treatment Alone in Patients with Atopic Dermatitis.
Lönndahl L; Holst M; Bradley M; Killasli H; Heilborn J; Hall MA; Theodorsson E; Holmberg J; Nordlind K
Acta Derm Venereol; 2018 Mar; 98(3):324-328. PubMed ID: 29182791
[TBL] [Abstract][Full Text] [Related]
14. [Acute sensory neuropathy associated with Hodgkin's lymphoma: a case study].
Yokota Y; Mitsuke K; Minami H; Morita A; Takahashi H; Kamei S
Rinsho Shinkeigaku; 2019 Jun; 59(6):349-355. PubMed ID: 31142709
[TBL] [Abstract][Full Text] [Related]
15. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy.
Ständer S; Siepmann D; Herrgott I; Sunderkötter C; Luger TA
PLoS One; 2010 Jun; 5(6):e10968. PubMed ID: 20532044
[TBL] [Abstract][Full Text] [Related]
16. [Role of aprepitant in the management of pruritus in a patient with cutaneous T-cell lymphoma].
Palacios Zabalza I; López de Torre Querejazu A; Santos Ibañez A
Farm Hosp; 2014 Apr; 38(2):145-7. PubMed ID: 24669900
[TBL] [Abstract][Full Text] [Related]
17. Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU).
Tsianakas A; Zeidler C; Riepe C; Borowski M; Forner C; Gerss J; Metz M; Staubach P; Raap U; Kaatz M; Urban M; Luger TA; Ständer S
Acta Derm Venereol; 2019 Apr; 99(4):379-385. PubMed ID: 30653242
[TBL] [Abstract][Full Text] [Related]
18. Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial.
Cole PD; McCarten KM; Pei Q; Spira M; Metzger ML; Drachtman RA; Horton TM; Bush R; Blaney SM; Weigel BJ; Kelly KM
Lancet Oncol; 2018 Sep; 19(9):1229-1238. PubMed ID: 30122620
[TBL] [Abstract][Full Text] [Related]
19. Gastroparesis-associated refractory nausea treated with aprepitant.
Fahler J; Wall GC; Leman BI
Ann Pharmacother; 2012 Dec; 46(12):e38. PubMed ID: 23191934
[TBL] [Abstract][Full Text] [Related]
20. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
